Oxandrolone use causes dyslipidemia in resistance-training practitioners

Authors

DOI:

https://doi.org/10.33448/rsd-v13i9.46803

Keywords:

Oxandrolone; Blood; Saliva; Resistance training; Anabolic agents; Dyslipidemia.

Abstract

Objective: This study investigated blood and salivary parameters in male resistance-training practitioners (RTP) using oxandrolone (OG) and compared with references values and control group (CG), in triplicate. Methods: Blood, saliva, and urine were collected from 22 individuals (OG, n = 11 / CG, n = 11) and analyzed: before oxandrolone (OX) consumption (T1), at cessation of OX use (T2), and three months after cessation of OX use (T3). Complete blood count, lipid profile, metabolites, and enzymes were analyzed from blood samples. Salivary flow, pH, triglycerides, urea, aspartate animotransferase, alanine aminotransferase, phosphorus, and calcium were analyzed from saliva. Urinalysis was used for toxicological screening. Results: A reduced hdl cholesterol level was observed in the og group (24 mg/dL) compared with the reference value (>40 mg/dL) at T2. HDL levels return to normal after cessation AT T3 (49 mg/dL, >40 mg/dL). A higher triglyceride level (177 mg/dL) was verified in OG group compared with the reference value (<175 mg/dL) at T3. Conclusions: The results of this study suggest that oxandrolone use is associated with changes in lipid profiles, including lower HDL levels and higher triglyceride levels, which are characteristic of dyslipidemia. however, while these findings indicate an association, they do not establish definitive causality. further research, including well-controlled longitudinal studies, is needed to confirm the causal relationship between oxandrolone use and dyslipidemia.

References

Alpdemir, M., Eryilmaz, M., Alpdemir, M. F., Topçu, G., Azak, A., & Yücel, D. (2018). Comparison of Widely Used Biochemical Analytes in the Serum and Saliva Samples of Dialysis Patients. Journal of Medical Biochemistry, 37(3), 346–354. https://doi.org/10.1515/jomb-2017-0056

Arazi, H. (2018). Effects of longitudinal abuse of anabolic steroids on liver enzymes activity and lipid profiles of male bodybuilders. Progress in Nutrition, 20(3), 323–328. https://doi.org/10.23751/pn.v20i3.5287

Graham, M. R., Davies, B., Grace, F. M., Kicman, A., & Baker, J. S. (2008). Anabolic steroid use: patterns of use and detection of doping. Sports medicine, 38(6), 505–525. https://doi.org/10.2165/00007256-200838060-00005

Basílio, I. L. D., Matos, A. P. R., Parente, G. V. U., & Oliveira, J. M. (2016). Análise do líquido ascítico de pacientes portadores de doença hepática. Revista Saúde e Ciência, 5(1), 23–36. DOI missed: https://doi.org/10.35572/rsc.v5i1.201

Bates, G., Van Hout, M. C., Teck, J. T. W., & McVeigh, J. (2019). Treatments for people who use anabolic androgenic steroids: a scoping review. Harm Reduction Journal, 16(1), 75. https://doi.org/10.1186/s12954-019-0343-1

Beckman Coulter, Inc. (2020). Beckman Coulter, Inc. Https://Www.Beckmancoulter.Com/En/Support. https://www.beckmancoulter.com/

Bick. (1993). Hematology: clinical and laboratory practice (R. L. Bick, Ed.). Mosby Inc.

Castro-Silva, I. I., Carvalho, M. A. F., Basílio, S. R., Farias Júnior, M. V. M., & Maciel, J. A. C. (2017). Relação Entre Alterações Salivares E Terapia Medicamentosa Em Adultos Jovens : Um Estudo Transversal Relation Between Salivary Alterations and Drug Therapy in Young Adults : a Cross - Sectional Study. Brazilian Journal of Surgery and Clinical Research, 18(2), 17–24.

Cheung, A. S., & Grossmann, M. (2018). Physiological basis behind ergogenic effects of anabolic androgens. Molecular and Cellular Endocrinology, 464, 14–20. https://doi.org/10.1016/j.mce.2017.01.047

Cheung, M. C., Albers, J. J., Wahl, P. W., & Hazzard, W. R. (1980). High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs. Atherosclerosis, 35(3), 215–228. https://doi.org/10.1016/0021-9150(80)90121-5

Davis, S. M., Cox-Martin, M. G., Bardsley, M. Z., Kowal, K., Zeitler, P. S., & Ross, J. L. (2017a). Effects of oxandrolone on cardiometabolic health in boys with klinefelter syndrome: A randomized controlled trial. Journal of Clinical Endocrinology and Metabolism, 102(1), 176–184. https://doi.org/10.1210/jc.2016-2904

Gil, A. C. (2017). Como elaborar projetos de pesquisa. 6 ed. Atlas.

Glueck, C. J., Ford, S., Steiner, P., & Fallat, R. (1973). Triglyceride removal efficiency and lipoprotein lipases: Effects of oxandrolone. Metabolism, 22(6), 807–814. https://doi.org/10.1016/0026-0495(73)90051-6

Grunfeld, C., Kotler, D. P., Dobs, A., Glesby, M., & Bhasin, S. (2006). Oxandrolone in the treatment of HIV-associated weight loss in men: A randomized, double-blind, placebo-controlled study. Journal of Acquired Immune Deficiency Syndromes, 41(3), 304–314. https://doi.org/10.1097/01.qai.0000197546.56131.40

Hartgens, F., & Kuipers, H. (2004a). Effects of androgenic-anabolic steroids in athletes. Sports Medicine, 34(8), 513–554. https://doi.org/10.2165/00007256-200434080-00003

Hartgens, F., Rietjens, G., Keizer, H. A., Kuipers, H., & Wolffenbuttel, B. H. R. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). British Journal of Sports Medicine, 38(3), 253–259. https://doi.org/10.1136/bjsm.2003.000199

Horwitz, H., Andersen, J. T., & Dalhoff, K. P. (2019). Health consequences of androgenic anabolic steroid use. Journal of Internal Medicine, 285(3), 333–340. https://doi.org/10.1111/joim.12850

Llewellyn’s, W. (2010). Anabolics (10th ed.). Molecular Nutrition.

Oliveira, J. E. P. O., Montenegro Júnior, R. M., Júnior, R. M. M., & Vencio, S. (2018). Diretrizes da Sociedade Brasileira de Diabetes 2017-2018. https://edisciplinas.usp.br/pluginfile.php/4925460/mod_resource/content/1/diretrizes-sbd-2017-2018.pdf

Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., Rifai, N., Smith, S. C., Taubert, K., Tracy, R. P., & Vinicor, F. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation, 107(3), 499–511. https://doi.org/10.1161/01.CIR.0000052939.59093.45

Pereira, E., Moyses, S. J., Ignácio, S. A., Mendes, D. K., Da Silva, D. S., Carneiro, E., Hardy, A. M. T. G., Rosa, E. A. R., Bettega, P. V. C., & Johann, A. C. B. R. (2019). Anabolic steroids among resistance training practitioners. PLoS ONE, 14(10), 1–13. https://doi.org/10.1371/journal.pone.0223384

Pierre, G., & Ciriades, J. (2009). Manual de Patologia Clínica - Ciriades. Atheneu.

Rosca, A. E., Stancu, C. S., Badiu, C., Popescu, B. O., Mirica, R., Căruntu, C., Gologan, S., Voiculescu, S. E., & Zagrean, A. M. (2019). Lipid profile changes induced by chronic administration of anabolic androgenic steroids and taurine in rats. Medicina (Lithuania), 55(9). https://doi.org/10.3390/medicina55090540

Scartezini M, Ferreira CES, Izar MCO, Bertoluci M, Vencio S, Campana GA, et al. Posicionamento sobre a Flexibilização do Jejum para o Perfil Lipídico. Arq Bras Cardiol. 2017; 108(3):195-197. https://doi.org/10.5935/abc.20170039

Schroeder, E. T., Zheng, L., Yarasheski, K. E., Qian, D., Stewart, Y., Flores, C., Martinez, C., Terk, M., & Sattler, F. R. (2004). Treatment with oxandrolone and the durability of effects in older men. Journal of Applied Physiology, 96(3), 1055–1062. https://doi.org/10.1152/japplphysiol.00808.2003

Siemens Healthcare Diagnósticos S.A. (2020). Siemens Healthcare Diagnósticos. Https://Www.Siemens-Healthineers.Com/Br/Support-Documentation/Online-Services/Document-Library. https://www.siemens-healthineers.com/br

Souza, F. R. de, Dos Santos, M. R., Porello, R. A., Fonseca, G. W. P. da, Sayegh, A. L. C., Lima, T. P., Ferreira, F. D., Oliveira, T. F. de, Yonamine, M., Takayama, L., Pereira, R. M. R., Negrão, C. E., Passarelli, M., Rochitte, C. E., & Alves, M. J. de N. N. (2019). Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users. Atherosclerosis, 283. 100–105. https://doi.org/10.1016/j.atherosclerosis.2019.02.006

Woyceichoski, I. E. C., Costa, C. H., de Araújo, C. M., Brancher, J. A., Resende, L. G., Vieira, I., & de Lima, A. A. S. (2013). Salivary buffer capacity, pH, and stimulated flow rate of crack cocaine users. Journal of Investigative and Clinical Dentistry, 4(3), 160–163. https://doi.org/10.1111/j.2041-1626.2012.00126.x

Wu, A. H. B. (2006). Tietz Clinical Guide to Laboratory Tests. https://books.google.com/books?hl=en&lr=&id=aQqjBQAAQBAJ&pgis=1

Downloads

Published

21/09/2024

How to Cite

GREBOGGY, D. de L. .; PEREIRA, E.; OLIVEIRA, T. F. de .; BATISTA, T. B. D. .; OLIVEIRA, S. E. F. de .; BIRK, L. .; BARROS, L. C. S. de .; JESUS, J. S. de .; MARTINS, P. .; AULER, F. .; CHAVES, M. H. M. .; WERNECK, R. I. .; TIBONI, F. .; BARROS, M. M. T. de .; ROSA, E. A. R. .; SANTOS, M. F. dos .; PAROLIN, S. A. E. C. .; CARNEIRO, E.; GAMA, Y. Y. da .; IGNÁCIO, S. A. .; BRANCHER, J. A. .; SCHEEREN, E. M. .; MARINS, M. H. .; JOHANN , A. C. B. R. . Oxandrolone use causes dyslipidemia in resistance-training practitioners. Research, Society and Development, [S. l.], v. 13, n. 9, p. e7113946803, 2024. DOI: 10.33448/rsd-v13i9.46803. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/46803. Acesso em: 27 sep. 2024.

Issue

Vol. 13 No. 9

Section

Health Sciences

License

Copyright (c) 2024 Dênis de Lima Greboggy; Ericson Pereira; Tiago Franco de Oliveira; Thiago Beltrami Dias Batista; Sarah Eller Franco de Oliveira; Letícia Birk; Leonardo Cesar Santos de Barros; Julia Souto de Jesus; Pamela Martins; Flavia Auler; Maria Heloisa Madruga Chaves; Renata Iani Werneck; Fernanda Tiboni; Marlene Maria Tourais de Barros; Edvaldo Antonio Ribeiro Rosa; Milena Fernandes dos Santos; Salma Ali El Chab Parolin; Everdan Carneiro; Yesudian Yamada da Gama; Sérgio Aparecido Ignácio; João Armando Brancher; Eduardo Mendonça Scheeren; Mariana Hornung Marins; Aline Cristina Batista Rodrigues Johann

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.